Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma - Scorecard - MDSpire
Advertisement
Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma
Clinical Scorecard: Identification of DLL3 as a Therapeutic Target in Glioblastoma Through Machine Learning and Development of a DLL3-Binding Cyclic Peptide
At a Glance
Category
Detail
Condition
Glioblastoma (GBM)
Key Mechanisms
DLL3 as a Notch pathway-related ligand with selective expression in GBM and minimal presence in normal brain tissue.
Target Population
Patients with glioblastoma, particularly those with recurrent disease.
Care Setting
Oncology and neuro-oncology settings focusing on targeted therapies.
Key Highlights
DLL3 identified as a promising target for GBM therapy.
Cyclic peptide IMP-3 shows selective binding to DLL3.
Machine learning and transcriptomic profiling utilized for target identification.
DLL3 has high discriminative power and prognostic relevance in GBM.
Targeted radionuclide therapy may improve treatment outcomes in GBM.
Guideline-Based Recommendations
Diagnosis
Utilize transcriptomic profiling for identifying potential biomarkers in GBM.
Management
Consider DLL3-targeted therapies in the treatment of glioblastoma.
Monitoring & Follow-up
Assess DLL3 expression levels as a prognostic indicator.
Risks
Potential for therapy resistance due to intratumoral heterogeneity.
Patient & Prescribing Data
Adults diagnosed with glioblastoma, particularly those with limited treatment options.
DLL3-targeted therapies may offer a novel approach to overcoming treatment resistance.
Clinical Best Practices
Integrate machine learning approaches in biomarker discovery.
Utilize cyclic peptides for targeted delivery in brain tumors.
Focus on tumor-selective molecular vulnerabilities for therapeutic strategies.
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
